Analysis of HBV Marker Test among Chinese Blood Donors from 2017 to 2023

doi:10.3969/j.issn.1671-2587.2025.04.006

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2025, Vol. 27 ›› Issue (4): 470-478.DOI: 10.3969/j.issn.1671-2587.2025.04.006

Previous Articles Next Articles

Analysis of HBV Marker Test among Chinese Blood Donors from 2017 to 2023

BAO Jingjing¹, WANG Yunqiang², ZHANG Jian³, LIU Fufa⁴, WANG Lin⁵, YAN Feng⁶, LI Li⁷, WANG Zhenxing⁸, LIU Yajun⁹, ZHANG Wei¹⁰, LI Ying¹¹, YU Qin¹², ZOU Binbin¹³, ZHAO Yuwei¹⁴, ZHU Xiangming¹⁵, FENG Weiping¹⁶, LI Yujun¹⁷, TANG Fei¹⁸, LU Ranran¹⁹, QIU Changwen²⁰, DUAN Yong²¹, WEN Tao²², WAN Yanhong²³, LIU Dong²⁴, YUAN Xiaohua²⁵, ZHANG Qian²⁶, YANG Zhongsi²⁷, QIU Yan²⁸

¹Nanjing Red Cross Blood Center, Nanjing, Jiangsu 210000;
²Qinhuangdao Central Blood Station, Qinhuangdao, Hebei 066000;
³Yancheng Central Blood Station, Yancheng, Jiangsu 224000;
⁴Ganzhou Central Blood Station, Ganzhou, Jiangxi 341000;
⁵Hainan Provincial Blood Center, Haikou, Hainan 570000;
⁶Handan Central Blood Station, Handan, Hebei 056000;
⁷Huaian Central Blood Station, Huaian, Jiangsu 223200;
⁸Dongguan Central Blood Station, Dongguan, Guangdong 523000;
⁹Xianyang Central Blood Station, Xianyang, Shaanxi 712000;
¹⁰Beijing Tongzhou Central Blood Station, Beijing 101100;
¹¹Jiangxi Provincial Blood Center, Nanchang, Jiangxi 330000;
¹²Wuhan Blood Center, Wuhan, Hubei 430000;
¹³Changsha Blood Center, Changsha, Hunan 410000;
¹⁴Chengdu Blood Center, Chengdu, Sichuan 610000;
¹⁵Kunming Blood Center of Yunnan Province, Kunming, Yunnan 650000;
¹⁶Red Cross Blood Center of Gansu Province, Lanzhou, Gansu 730000;
¹⁷Ningxia Hui Autonomous Region Blood Center, Yinchuan, Ningxia Hui Autonomous Region 750000;
¹⁸Guizhou Provincial Blood Center, Guiyang, Guizhou 550000;
¹⁹Chifeng Central Blood Station, Chifeng, Inner Mongolia Autonomous Region 024000;
²⁰Nanning Central Blood Station, Nanning, Guangxi 530000;
²¹Shaanxi Provincial Blood Center, Xi'an, Shaanxi 710000;
²²Red Cross Blood Center of Henan Province, Zhengzhou, Henan 450000;
²³Taiyuan Blood Center, Taiyuan, Shanxi 030000;
²⁴Chongqing Blood Center, Chongqing 400000;
²⁵Urumqi Blood Center, Urumqi, Xinjiang Uyghur Autonomous Region 830000;
²⁶Baoji Central Blood Station, Baoji, Shaanxi 721000;
²⁷Qingdao Central Blood Station, Qingdao, Shandong 266000;
²⁸Beijing Red Cross Blood Center, Beijing 100000

Received:2024-12-03 Published:2025-08-22

Abstract

Abstract: Objective To understand the prevalence of HBV (hepatitis B virus) infection among blood donors in China by analyzing the results of different HBV marker tests in 32 Blood Stations. Methods Relevant data were collected from the Practice Comparison information management system of Blood Transfusion Service in Mainland China. Data on first-time and repeated blood donors from 32 Blood Stations between 2017 and 2023 who had tested positive for different HBV markers were selected. The rates of HBsAg (hepatitis B surface antigen) ELISA (enzyme-linked immunosorbent assay), HBV DNA (deoxyribonucleic acid) test failure rates among ELISA-qualified samples, and overall HBV test failure were calculated for each blood station, and statistical analyses were conducted. Results From 2017 to 2023, the range of HBsAg ELISA test failure rates among first-time blood donors was 51.69/10 000 to 76.44/10 000 (the median is 58.75/10 000), while for repeated blood donors, the range was 9.17/10 000 to 18.62/10 000 (the median is 14.05/10 000). The range of HBV DNA test failure rates was 6.26/10 000 to 8.32/10 000 (the median is 7.14/10 000), and the range of overall HBV test failure rates was 36.51/10 000 to 58.86/10 000 (the median is 43.76/10 000). Conclusion Although there were fluctuations, the overall rates of HBsAg ELISA test failure, HBV DNA test failure rates among ELISA-qualified samples, and overall HBV test failure showed a downward trend. The distribution of HBV infection among blood donors in China is regional.

Key words: Hepatitis B virus, First-time blood donors, Repeated blood donors, HBsAg ELISA, HBV DNA

CLC Number:

R512.6⁺2

BAO Jingjing, WANG Yunqiang, ZHANG Jian, LIU Fufa, WANG Lin, YAN Feng, LI Li, WANG Zhenxing, LIU Yajun, ZHANG Wei, LI Ying, YU Qin, ZOU Binbin, ZHAO Yuwei, ZHU Xiangming, FENG Weiping, LI Yujun, TANG Fei, LU Ranran, QIU Changwen, DUAN Yong, WEN Tao, WAN Yanhong, LIU Dong, YUAN Xiaohua, ZHANG Qian, YANG Zhongsi, QIU Yan. Analysis of HBV Marker Test among Chinese Blood Donors from 2017 to 2023[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 470-478.

References

[1] ASANDEM D A,SEGBEFIA S P,KUSI K A,et al.Hepatitis B virus infection:a mini review[J]. Viruses,2024,16(5):724.
[2] CANDOTTI D,BOIZEAU L,LAPERCHE S.Occult hepatitis B infection and transfusion-transmission risk[J].Transfus Clin Biol,2017,24(3):189-195.
[3] 黄敏,白林,卢长春,等. 血站核酸筛查模式对输血传播 HBV残余风险影响的评估研究[J]. 中华实验和临床病毒学杂志,2022,36(4):429-435.
[4] 郭瑞,侯云,苏常山,等. 采用发病率-窗口期模型分析2018—2022年国内21家采供血机构输血传播HBV检测残余风险[J]. 临床输血与检验,2024,26(6):781-787.
[5] FADDY H M,OSIOWY C,CUSTER B,et al.International review of blood donation nucleic acid amplification testing[J]. Vox Sang,2024,119(4):315-325.
[6] 陈霄,毕岐勇,江峰,等. 2014—2020年北京地区全血献血者HBV相关标记物检测结果分析[J]. 北京医学, 2023,45(4):347-350.
[7] 中华人民共和国国家卫生健康委员会. 国家卫生计生委关于印发血站技术操作规程(2015版)的通知(国卫医发〔2015〕95号)[EB/OL].(2015-12-31)[2024-12-20].http://www.nhc.gov.cn/ylyjs/s7658/201512/d9c61cbe48c14b88ab82ebae72036223.shtml
[8] 中华人民共和国国家卫生健康委员会. 国家卫生健康委关于印发血站技术操作规程(2019版)的通知(国卫医函〔2019〕98号)[EB/OL].(2019-05-08)[2024-12-20].http://www.nhc.gov.cn/yzygj/s7658/201905/bdd4f4ccd15c4201bfb6d9e7492d7fab.shtml
[9] ALRASHDAN Y,AL-JAFF K,NAJDAWI M,et al.Occult hepatitis B in blood donation centers[J]. J Med Life, 2023,16(4):571-578.
[10] 田甜,邱艳,郭成城,等. 采供血机构执业比对信息管理系统的开发建设[J]. 临床输血与检验,2017,19(1):13-17.
[11] 郭成城,邱艳,张娟,等. 我国大陆采供血机构开展执业比对工作的现状[J]. 临床输血与检验,2017,19(1):4-7.
[12] 国家质量监督检验检疫总局. 献血者健康检查要求[S]. 2011.
[13] 谈维,英圣艳,成宁,等. 我国血站输血传播相关传染病标记物检测策略现状研究[J]. 中华实验和临床病毒学杂志, 2023,37(4):383-388.
[14] ALLAIN J P,OWUSU-OFORI S,YE X L,et al.Hepatitis B virus chronic infection in blood donors from Asian and African high or medium prevalence areas:comparison according to sex[J]. Viruses,2022,14(4):673.
[15] 王丁丁,沈有华,钟建玲,等. 我国18家地市级血站献血人群HBV感染情况分析[J]. 中国输血杂志,2023,36(2):172-176.
[16] 张莉,车忠民,李玉军,等. 2016—2022年我国17家血液中心献血者HBV感染相关标记物检测情况分析[J]. 北京医学,2024,46(8):1-7.
[17] YE X L,LI T,XU X X,et al.Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in Southern China[J]. Blood Transfus,2017,15(1):6-12.
[18] LELIE N,BUSCH M,KLEINMAN S.Residual risk of transfusion-transmitted hepatitis B virus (TT-HBV) infection by NAT-screened blood components:A review of observed versus modeled infectivity from donors with window period and occult HBV infections[J]. Transfusion, 2021,61(11);3190-3201.
[19] GAO Z,ZHANG Y,SHAN H,et al.A 30-year systematic review and meta-analysis of hepatitis B virus among blood donors in mainland China: revealing increase of new threats[J]. Transfusion,2017,57(8):1988-1997.
[20] 杜飞,刘青恋,付清培,等. 四川省乙型肝炎血清流行病学调查[J]. 中华流行病学杂志,2009,30(2):139-143.
[21] 姜洁,钱姣,朱立国,等. 江苏省2010年和2020年乙型肝炎血清流行病学特征分析[J]. 中华疾病控制杂志,2023, 27(2):238-243.
[22] 汪娟. 安徽省部分地区乙型肝炎分子流行病学初步研究[D]. 合肥:安徽医科大学,2011.
[23] PANICKER S,GIRISH KUMAR C P,SELVARAJ V,et al. Molecular epidemiology of HBV among HIV infected individuals in Chennai,south India[J]. Virus Res,2021, 300:198439.
[24] YOTSUYANAGI H,KUROSAKI M,YATSUHASHI H,et al.Characteristics and healthcare costs in the aging hepatitis B population of Japan:a nationwide real-world analysis[J]. Dig Dis,2022,40(1):68-77.
[25] LEE C H,CHOI G H,CHOI H Y,et al.Core indicators related to the elimination of hepatitis B and C virus infection in South Korea:a nationwide study[J]. Clin Mol Hepatol, 2023,29(3):779-793.
[26] ZHOU Y H,YU J H,ZHOU L,et al.Prevalence of antibody to hepatitis B surface antigen among qualified blood donors in Nanjing,China[J]. Hum Vaccin Immunother,2023,19(1):2206774.
[27] ZHONG L,XI G X,ZHANG L J,et al.The estimation of prevalence and risk factors of hepatitis B virus infection among blood donors in Chengdu,China[J]. J Med Virol, 2016,88(2):260-267.
[28] 赵冬雁,居兵,戚海,等. 国内20家采供血机构延迟献血的主要原因分析[J]. 中国输血杂志,2022,35(4):360-364.
[29] RAMACHANDRAN S,GROVES J A,XIA G L,et al.Recent and occult hepatitis B virus infections among blood donors in the United States[J]. Transfusion,2019, 59(2):601-611.
[30] LI H L,SONG W J,LI H Y,et al.Advances in isothermal nucleic acid amplification methods for hepatitis B virus detection[J]. Analyst,2023,148(16):3708-3718.
[31] 刘妍妍,黄霞,陈敏,等. 17家省级血液中心献血人群特征回顾性分析[J]. 临床输血与检验,2024,26(4):491-498.
[32] FERDOWSI S,MAGHSUDLU M,POURFATHOLLAH A A,et al.The impact of pre-donation viral markers screening of new blood donors on blood safety[J]. Transfus Clin Biol,2023,30(4):417-420.
[33] IM Y R,JAGDISH R,LEITH D,et al.Prevalence of occult hepatitis B virus infection in adults:a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2022,7(10):932-942.
[34] VAN DE LAAR T J,HOGEMA B M,MOLENAAR-DE BACKER M W,et al. Blood donor screening in the Netherlands:universal anti-HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing[J]. Transfusion,2021,61(7):2116-2124.
[35] NIKOLOPOULOU G B,TZOUTZAS I,TSAKRIS A,et al.Hepatitis B in healthcare personnel:an update on the global landscape[J]. Viruses,2023,15(12):2454.

Analysis of HBV Marker Test among Chinese Blood Donors from 2017 to 2023

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	ZHANG Qi, GUI Rong, LIU Juan, ZHANG Jun, ZHOU Lujie, LIU Fenghua, LV Xianping, HU Junhua, ZHOU Jun, MA Xinghuan, WANG Peng, YANG Jiangcun, DU Chunhong, LI Xiying, QIN Li, GONG Jiwu, XIA Rong. Analysis of Screening for HBV, HCV and HIV Infections in Patientswith Secondary Immunodeficiency [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(4): 478-483.
[2]	GUO Rui, HOU Yun, SU Changshan, et al. Assessing the Residual Risk of Hepatitis B Virus Transmission via Blood Transfusion in 21 Chinese Blood Centers from 2018 to 2022 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 781-786.
[3]	DENG Xuelian, ZANG Liang, LIU Xiaochun, SUN Peng, WANG Yingying, CANDOTTI Daniel, ZHOU Jun. Re-entry Strategy of Nucleic Acid Testing Reactive Blood Donors Based on HBV Infection Confirmation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 667-674.
[4]	HU Junhua, HAN Jianfeng, WANG Peng, et al. Nucleic Acid Testing and Clinical Characteristics of Immunological Gray Zone for HBV, HCV, and HIV in a Multi-center Study [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 675-679.
[5]	JIANG Tianqi, SUN Kewang, WANG Hao, et al. Serology and Characterization of Pre-S1 Gene in HBV-Infected Pregnant Women with Negative Pre-S1 Antigen [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(5): 662-666.
[6]	YAN Song-xia, WANG Hai-yan, JING Zhong-cui, et al. Association of Guillain-Barré Syndrome and Hepatitis B Virus Infection [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(2): 222-226.
[7]	A Multi-center Study CHENG Jin-feng, JIAO Wei, ZHOU Hong-xia, et al. Application of Hepatitis B Virus,Hepatitis C Virus and Human Immunodeficiency Virus Nucleic Acid Detection in Patients Undergoing Surgery [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 568-573.
[8]	DONG Hang, HUANG Xue-yuan, HE Li, et al. Multi-Center Study of Nucleic Acid Test for HBV,HCV and HIV Serological Weak-reactive Samples [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 579-582.
[9]	LIU Hai-ting, DENG Zhi-hua, CAI Dan, et al. Results of 10173 Hepatitis B Specimens Detected by Serologic Test and Nucleic Acid Testing [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(6): 583-586.
[10]	XIN Ju-mei. Clinical Significance of HBsAg and HBV DNA Quantitation in Patients with Chronic Hepatitis B and HBV-Related Liver Cirrhosis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(2): 203-205.
[11]	CHEN Wang, LIU Ai-ling, WU Min. Natural Resistance of HBV to LMV/ADV Treatments and Its Association with Genetic Structure in Shenzhen Region [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 619-622.
[12]	ZHU Li-juan, HAO Jia-yan, XU Li-li, et al. Evaluation of Serum Biomarkers of Hepatitis B Virus Among 42 509 Young Adults in Anhui Province [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(6): 646-648.
[13]	ZHANG Yu, SUN Guo-dong, ZHANG Li, et al. Serological Distribution Analysis of Occult Hepatitis B Virus in Blood Donors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(5): 480-484.
[14]	YAO Wei, WANG Jiu-xiang, HUO Xing-xing, et al. Analysis of HBV Genotyping and Drug-Resistance Associated Mutations [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(4): 428-430.
[15]	YANG Chuan-xin. Correlation and Clinical Significance of PreS1 Antigen and HBV Serological Markers and HBV-DNA [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(1): 53-55.